Keywords
1,2,4-triazole-3-carboxylates
acylamidrazones
antiviral agents
ribavirin full deoxy analogs
SARS-CoV2
Abstract
5-Substituted analogs of the ribavirin heterocyclic base showed significant antiviral activity against SARS-CoV2 together with reduced toxicity, compared to ribavirin. Using the SARS-CoV2 attachment model, it was found that 5-(pyridin-4-yl)-1,2,4-triazole-3-carboxamide and 5-(tetrahydrofuran-2-yl)-1,2,4-triazole-3-carboxamide, as well as the isosteric derivative of the latter, namely, 5-(tetrahydrofuran-2-yl)-1,2,4-triazole-3-carbothioamide could act through inhibiting viral attachment to the cell.
Funders
Ministry of Education and Science of the Russian Federation
075-15- 2025-548
References
1.
Geraghty R., Aliota M., Bonnac L.
Viruses,
2021
2.
De Clercq E., Li G.
Clinical Microbiology Reviews,
2016
3.
Nyström K., Waldenström J., Tang K., Lagging M.
Future Virology,
2019
4.
Ramírez-Olivencia G., Estébanez M., Membrillo F.J., Ybarra M.D.
Enfermedades Infecciosas y Microbiologia Clinica,
2019
5.
Chudinov M.V.
Fine Chemical Technologies,
2019
6.
Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G.
Cell Research,
2020
7.
Liu J., Zheng X., Tong Q., Li W., Wang B., Sutter K., Trilling M., Lu M., Dittmer U., Yang D.
Journal of Medical Virology,
2020
8.
Habib A.M., Ali M.A., Zouaoui B.R., Taha M.A., Mohammed B.S., Saquib N.
BMC Infectious Diseases,
2019
9.
Khalili J.S., Zhu H., Mak N.S., Yan Y., Zhu Y.
Journal of Medical Virology,
2020
10.
Liu C., Lu C., Wong S.H., Lin L.
Frontiers in Immunology,
2021
11.
Ferron F., Subissi L., Silveira De Morais A.T., Le N.T., Sevajol M., Gluais L., Decroly E., Vonrhein C., Bricogne G., Canard B., Imbert I.
Proceedings of the National Academy of Sciences of the United States of America,
2017
12.
Moeller N.H., Shi K., Demir Ö., Belica C., Banerjee S., Yin L., Durfee C., Amaro R.E., Aihara H.
Proceedings of the National Academy of Sciences of the United States of America,
2022
13.
Smith E.C., Blanc H., Vignuzzi M., Denison M.R.
PLoS Pathogens,
2013
14.
Vo N.V., Young K., Lai M.M.
Biochemistry,
2003
15.
CONTE E., MODICA A., CACOPARDO B., MESSINA L., NIGRO L., MESSINA A.
Parasite Immunology,
2005
16.
Parker W.B.
Virus Research,
2005
17.
Ogbomo H., Michaelis M., Altenbrandt B., Doerr H.W., Cinatl J.
Biochemical Pharmacology,
2010
18.
ref-10.71267-mendc7395-1-18-1-0
I. D. Konstantinova, M. V. Chudinov, A. N. Prutkov, A. V. Matveev, L. E. Grebenkina and E. V. Dorofeeva
2016
19.
Ekaterina Z., Daria S., Lyubov G., Ekaterina M., Varvara M., Diana G., Andrey M., Ekaterina L.
Current Pharmaceutical Design,
2023
20.
Grebenkina L.E., Prutkov A.N., Matveev A.V., Chudinov M.V.
Fine Chemical Technologies,
2022
21.
Grebenkina L.E., Matveev A.V., Chudinov M.V.
Chemistry of Heterocyclic Compounds,
2020
22.
Witkowski J.T., Robins R.K., Khare G.P., Sidwell R.W.
Journal of Medicinal Chemistry,
1973
23.
Zhurilo N.I., Chudinov M.V., Matveev A.V., Smirnova O.S., Konstantinova I.D., Miroshnikov A.I., Prutkov A.N., Grebenkina L.E., Pulkova N.V., Shvets V.I.
Bioorganic and Medicinal Chemistry Letters,
2018
24.
Gabrielsen B., Phelan M.J., Barthel-Rosa L., See C., Huggins J.W., Kefauver D.F., Monath T.P., Ussery M.A., Chmurny G.N.
Journal of Medicinal Chemistry,
1992
25.
Siniavin A.E., Streltsova M.A., Nikiforova M.A., Kudryavtsev D.S., Grinkina S.D., Gushchin V.A., Mozhaeva V.A., Starkov V.G., Osipov A.V., Lummis S.C., Tsetlin V.I., Utkin Y.N.
Cellular and Molecular Life Sciences,
2021
26.
Harrison C., Acharya K.R.
Journal of Cell Communication and Signaling,
2014
27.
Dutta K.
ACS Pharmacology & Translational Science,
2022
28.
Hochuli J.E., Jain S., Melo-Filho C., Sessions Z.L., Bobrowski T., Choe J., Zheng J., Eastman R., Talley D.C., Rai G., Simeonov A., Tropsha A., Muratov E.N., Baljinnyam B., Zakharov A.V., et. al.
ACS Pharmacology & Translational Science,
2022